Hematologic Toxicity Patterns and Prognostic Value of Complete Blood Count in Advanced HR-positive/HER2-negative Breast Cancer Treated with Palbociclib plus Letrozole: A Real-World Single-Center Study
Pharmaceutical Sciences · 31.10.2026 · 32 (4) · 632-639
DOI: 10.34172/ps.43631 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Sciences, online erschienen am 08.06.2026. Verfasst von Adnan Mustafa Isamail und 2 weiteren Autor:innen. Die Arbeit nennt 27 Literaturangaben.
Abstract (Originalsprache)
Introduction
The prognostic value of complete blood count (CBC) parameters in patients with advanced HR-positive/HER2-negative breast cancer receiving palbociclib plus letrozole remains unclear. This study aimed to characterize hematologic toxicity patterns associated with treatment response and survival in real-world setting.
Methods
This prospective single-center study included 80 women receiving palbociclib plus letrozole. CBC was collected at baseline and after each of six cycles. Toxicities were graded by CTCAE v5.0. Analyses were descriptive with repeated-measures ANOVA, and ROC curve analysis.
Results
Most hematologic toxicities were grade 1-2; grade 3-4 neutropenia was uncommon and no febrile events occurred. Higher mean WBC and RBC counts during treatment were significantly associated with non-response and shorter progression-free survival (PFS).
Conclusion
Palbociclib plus letrozole showed a manageable safety profile without cumulative hematologic toxicity. Higher on-treatment WBC and RBC counts are prognostic for poorer outcomes. Routine CBC monitoring may offer a low-cost tool to identify patients at risk for treatment failure.
Zitieren
APA
Isamail, A. M., Saleh, E. S., & Alsammarraie, A. Z. (2026). Hematologic Toxicity Patterns and Prognostic Value of Complete Blood Count in Advanced HR-positive/HER2-negative Breast Cancer Treated with Palbociclib plus Letrozole: A Real-World Single-Center Study. Pharmaceutical Sciences, 32(4), 632-639. https://doi.org/10.34172/ps.43631
Vancouver
Isamail AM, Saleh ES, Alsammarraie AZ. Hematologic Toxicity Patterns and Prognostic Value of Complete Blood Count in Advanced HR-positive/HER2-negative Breast Cancer Treated with Palbociclib plus Letrozole: A Real-World Single-Center Study. Pharmaceutical Sciences. 2026;32(4):632-639. doi:10.34172/ps.43631
BibTeX
@article{Isamail2026,
author = {Isamail, Adnan Mustafa and Saleh, Eman Saadi and Alsammarraie, Ahmed Zuhair},
title = {Hematologic Toxicity Patterns and Prognostic Value of Complete Blood Count in Advanced HR-positive/HER2-negative Breast Cancer Treated with Palbociclib plus Letrozole: A Real-World Single-Center Study},
journal = {Pharmaceutical Sciences},
year = {2026},
volume = {32},
number = {4},
pages = {632--639},
doi = {10.34172/ps.43631}
}
EUVIMED